Predict your next investment

ITOCHU CHEMICAL FRONTIER Corporation company logo
Corporation
INDUSTRIAL | Basic Materials / Chemical Distribution
itcchem.co.jp

See what CB Insights has to offer

Investments

2

About ITOCHU CHEMICAL FRONTIER Corporation

ITOCHU CHEMICAL FRONTIER Corporation, a fully-owned subsidiary of ITOCHU Corporation, focuses on the domestic and international trade, wholesale, consignment processing, and its mediation of such materials as organic chemicals, fine chemicals, functional materials, pharmaceutical, agrochemicals, feed additives and those raw materials and intermediates.

ITOCHU CHEMICAL FRONTIER Corporation Headquarter Location

5-1, Kita-Aoyama 2-chome Minato-ku

Tokyo, 107-0061,

Japan

+81-3-3497-4510

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

ITOCHU CHEMICAL FRONTIER Corporation Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ITOCHU CHEMICAL FRONTIER Corporation Rank

Latest ITOCHU CHEMICAL FRONTIER Corporation News

ITOCHU Announces a Capital and Business Tie-up with chromocenter Inc.

Jul 18, 2020

Primary contents from here. July 13, 2020 ITOCHU Corporation (headquartered in Minato-ku, Tokyo; Yoshihisa Suzuki, President & COO; hereinafter “ITOCHU”) announced today that it has formed a capital and business tie-up with chromocenter Inc. (headquartered in Yonago-shi, Tottori; Takashi Matsuoka, President and Representative Director; hereinafter “chromocenter”), a Tottori University venture that supports the research and development of pharmaceutical products. One strength of chromocenter lies in its expertise in technologies related to chromosome engineering. In addition to providing the chromosome analysis service that is its mainstay business, the company receives orders from pharmaceutical companies for the creation of cells for the making of biologics and for the development of gene therapies based on artificial chromosome vector technologies. In recent years, biologics, including those used for cancer therapies, are among the top-selling pharmaceutical products. However, complicated manufacturing methods and high cost have been issues in biologics. It is expected that chromocenter will contribute to the further spread of biologics by reducing manufacturing costs through the provision of CHO cells,* its originally established cell line, in addition to improving manufacturing quality control with its mainstay business, the chromosome analysis service. Under the capital and business tie-up, ITOCHU will help chromocenter reinforce its structure for domestic and overseas sales of the chromosome analysis service, its mainstay business. ITOCHU will also work together with ITOCHU CHEMICAL FRONTIER Corporation (headquartered in Minato-ku, Tokyo; Tustomu Miyazaki, President & CEO) to promote multilateral expansion of the business in the pharmaceutical industry, including not only low-molecular drugs but also the fields of regenerative medicine and cell therapy. *Features of the original CHO cell lines chromacenter's proprietary technologies have enabled establishment of a new CHO cell lines. These cells from chromocenter enable high-yield, low-cost production of a protein which used to be difficult to produce with colibacilli or yeast. They enable the production of protein materials not only as pharmaceutical materials but also for a wide range of fields such as functional foods, cosmetics, and chemical products. Overview of ITOCHU

ITOCHU CHEMICAL FRONTIER Corporation Investments

2 Investments

ITOCHU CHEMICAL FRONTIER Corporation has made 2 investments. Their latest investment was in Heartseed as part of their Series C on June 6, 2021.

CBI Logo

ITOCHU CHEMICAL FRONTIER Corporation Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/11/2021

Series C

Heartseed

$37M

No

2

3/10/2020

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/11/2021

3/10/2020

Round

Series C

Series B - II

Company

Heartseed

Subscribe to see more

Amount

$37M

$99M

New?

No

Subscribe to see more

Co-Investors

Sources

2

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.